Dr. Reddy's Laboratories Ltd. NSE: DRREDDY | BSE: 500124

Turnaround Potential

Download real time

1316.70 13.60 (1.04%)

29.09% Gain from 52W Low

1.1M

NSE+BSE Volume

NSE 12 Sep, 2025 3:31 PM (IST)

Acquisition

Dr. Reddy's Labs to buy JNJ's Stugeron portfolio for $50.5 mn to foray into the anti-vertigo space See details

Dr. Reddy's Laboratories Ltd. share price target

Dr. Reddy's Laboratories Ltd. has an average share price target of 1278.56. The consensus estimate represents a downside of -2.90% from the last price of 1316.70. View 18 reports from 9 analysts offering long-term price targets for Dr. Reddy's Laboratories Ltd..

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Load latest Google or static link led you to an intermediate page.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	14 Sep 2025	Dr. Reddy's Labs	Consensus Share Price Target	1316.70	1287.37	-	-2.23	hold	pdf Detailed Estimates
	20 May 2022	Dr. Reddy's Labs	Motilal Oswal Reco Target	1316.70	4800.00	4249.10 (-69.01%)	Target met	Buy	pdf post cache		Broker Report Efforts on track to sustain robust launches across markets Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	20 May 2022	Dr. Reddy's Labs	ICICI Direct	1316.70	4800.00	4249.10 (-69.01%)	Target met	Buy	pdf post cache		Broker Report Dr Reddy's Laboratories ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	20 May 2022	Dr. Reddy's Labs	ICICI Direct	1316.70	4800.00	4249.10 (-69.01%)	Target met	Buy	pdf post cache		Broker Report Ashok Leyland ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	31 Jan 2022	Dr. Reddy's Labs	BOB Capital Markets Ltd. Target	1316.70	4700.00	4302.80 (-69.40%)	Pre-Bonus/ Split	Hold	pdf post cache		Broker Report Dr Reddy's Labs (HOLD): Stable quarter, US price erosion continues; cut to HOLD BOB Capital Markets Ltd. Growth in Q3 driven by product launches and higher volumes, partly offset by US price erosion pdf Copy Link Share on Share on Share on Share on Alert
	29 Jan 2022	Dr. Reddy's Labs	ICICI Securities Limited Reco Target	1316.70	5160.00	4218.60 (-68.79%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report Dr Reddy's Laboratories ICICI Securities Limited Numbers in line; launches in FY23 likely drivers APIs, custom pharmaceutical services, biosimilar and complex formulations. It has 13 formulation facilities, nine API manufacturing facilities, one biologics facility and several R&D centres across the globe Q3FY22 Results: Reported steady set of numbers despite Covid revenue vacuum this quarter, in line with our estimates.... pdf Copy Link Share on Share on Share on Share on Alert
	01 Jan 2022	Dr. Reddy's Labs	Sharekhan	1316.70	5900.00	4907.00 (-73.17%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report Dr Reddys Labs Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
	01 Jan 2022	Dr. Reddy's Labs	Sharekhan	1316.70	5900.00	4907.00 (-73.17%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report Dr Reddys Labs Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
	09 Nov 2021	Dr. Reddy's Labs	Geojit BNP Paribas Target	1316.70	5437.00	4843.25 (-72.81%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report DR. REDDY'S LABORATARIES Geojit BNP Paribas Company is expected to fare well on the back drop of continued growth in revenue along with innovation of new drugs and medications. Hence, we reiterate our BUY rating on the stock with a revised target price of Rs. 5,437 using a target multiple of 23x FY23E adj. EPS. Topline aided by new Medications Q2FY22 revenue grew 17.8% YoY to Rs. 5,787cr, driven by significant growth in Global Generics segment (+19.0% YoY to Rs. 4,747cr) and robust performance from Proprietary Products segment (Rs. 123cr vs Rs. 10cr in Q2FY21, on the account of... pdf Copy Link Share on Share on Share on Share on Alert
	08 Nov 2021	Dr. Reddy's Labs	SMC online	1316.70		4792.35 (-72.52%)	Pre-Bonus/ Split	Results Update	pdf post cache		Broker Report Dr. Reddy SMC online segment rose 1,132.00% to Rs 123.20 crore (accounting for 2.07% of total sales). Sales of (accounting for 17.12% of total sales). Sales of Global Generics segment has gone up 19.03% Others segment has gone up 13.96% to Rs 59.60 crore (accounting for 1.00% of total sales). Inter-segment sales came down from Rs 175.10 crore to Rs 161.80 crore.... pdf Copy Link Share on Share on Share on Share on Alert
	28 Jul 2021	Dr. Reddy's Labs	Axis Direct Target	1316.70	5600.00	4731.75 (-72.17%)	Pre-Bonus/ Split	Buy	pdf post cache		Broker Report Result Update:Dr Reddys Labs Axis Direct The company already has launched Sputnik-V in the Indian Market with the capacity to manufacture 26 Cr doses in a year. Further, the investigation is ongoing in the US court against few healthcare professionals from Ukraine and other CIS countries for improper payment practices. pdf Copy Link Share on Share on Share on Share on Alert
more loading

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners